Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.
David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.
Our bite-sized study summaries include new research on antiretrovirals in development, trends in antiretroviral initiation speed and viral suppression rates in the U.S., and the link between gender-affirming surgery and an undetectable viral load.
March 11, 2021: Anticholinergic medications and neurocognitive issues; weight gain and dolutegravir in older men; drug interaction risks on B/F/TAF; real-world efficacy of HBV-active HIV treatment.
Arriving on the one-year anniversary of nationwide COVID-19 shutdowns, the 2021 Conference on Retroviruses and Opportunistic Infections won't be in person this year—but it will emphasize COVID-19 alongside important HIV prevention and treatment updates.
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.